A Multicentre Study of 244 Pregnancies in Women with Undifferentiated Connective Tissue Disease: Foetal/Perinatal and Maternal Outcomes and Disease Evolution Towards a Definite Connective Tissue Disease

Massimo Radin¹, Karen Schreiber ², Irene Cecchi ¹, Alessandra Bortoluzzi ³, Francesca Crisafulli ⁴, Cristiano M. De Freitas ⁵, Beatrice Bacco ¹, Elena Rubini ¹, Silvia Grazietta Foddai ¹, Melissa Padovan ³, Silvia Gallo Cassarino ¹, Franco Franceschini ⁶, Danieli Andrade ⁷, Chiara Benedetto ⁸, Marcello Govoni ⁹, Tiziana Bertero ¹, Luca Marozio ¹, Dario Roccatello ¹, Laura Andreoli ⁴ and Savino Sciascia ¹⁰, ¹University of Turin, Turin, Italy, ²Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark, ³University of Ferrara, Ferrara, Italy, ⁴University of Brescia, Brescia, Italy, ⁵Universidade de Sao Paolo, San Paolo, Brazil, ⁶Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy, ⁷Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁸University of Turin, Turin, Piemonte, Italy, ⁹University of Ferrara, Rheumatology Unit, Ferrara, Italy, ¹⁰Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Connective tissue diseases, Multicenter study, pregnancy, risk assessment and patient outcomes

Session Information

Date: Tuesday, November 12, 2019

Title: Reproductive Issues In Rheumatic Disorders Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Undifferentiated connective tissue disease(UCTD) represents a common autoimmune condition in clinical practice, however, therapeutic strategies and follow-up are mostly based on clinician expertise. Little is known about the fetal and maternal pregnancy outcomes of women with UCTD. In this study, we aimed to investigate fetal/perinatal and maternal outcomes from a large multicentre cohort of women diagnosed with UCTD.

Methods: This multicenter study included patients diagnosed with UCTD ever pregnant, positive for antinuclear auto-antibodies and aged < 45 years old at study inclusion. Clinical data was collected retrospectively and complete laboratory profiles were assessed before conception, according to local standard of care adopted by all centers involved in the study.

Results: The study included a total of 133 women diagnosed with UCTD. Of the 224 pregnancies analysed,177 (79%) resulted in live births, 45 (20.1%) in miscarriages (defined as pregnancy loss before 12 weeks’ gestation), 2 (0.9%) in stillbirths (pregnancy loss after 20 weeks’ gestation) and six (2.7%) cases presented intrauterine growth restriction. Miscarriages and stillbirths were strongly associated with the presence of antiphospholipid antibodies (aPL) and extractable nuclear antigen antibodies (ENA).Maternal pregnancy complications were as follows: 5(2.2%) cases developed pre-eclampsia, 11 (4.9%) patients experienced gestational hypertension, and 12 (5.4%) women were diagnosed with gestational diabetes.

Joint involvement represented the most frequent clinical manifestation (57.9%), followed by Raynaud’s phenomenon (10.6%), photosensitivity (32.3%) and haematological manifestations (27.1%).

The rate of disease evolution of our cohort from a diagnosis of UCTD to a diagnosis of definite connective tissue disease (CTD) was 12% within a mean time of 5.3 years (S.D. ±2.8). With a total follow-up after first pregnancy of 1417 patient-years, we observed the evolution to a defined CTD in one for every 88 patient years. Demographic and diagnostic characteristics of the cohort are displayed in Table 1 and Table2 resumes pregnancy outcomes data.

Conclusion: Women with UCTD may warrant specialist follow-up when planning a pregnancy. ENA profiling and aPL testing should be mandatory in this setting, and further therapeutic approaches and management should be planned accordingly.

Table 1. Demographic and diagnostic characteristics of the cohort

Table2. Pregnancy Outcomes

Table 3. Therapy undertaken by the patients before, during and after pregnancy.

Disclosure: M. Radin, None; K. Schreiber, None; I. Cecchi, None; A. Bortoluzzi, None; F. Crisafulli, None; C. De Freitas, None; B. Bacco, None; E. Rubini, None; S. Foddai, None; M. Padovan, None; S. Gallo Cassarino, None; F. Franceschini, None; D. Andrade, None; C. Benedetto, None; M. Govoni, None; T. Bertero, None; L. Marozio, None; D. Roccatello, None; L. Andreoli, None; S. Sciascia, None.

To cite this abstract in AMA style:

Radin M, Schreiber K, Cecchi I, Bortoluzzi A, Crisafulli F, De Freitas C, Bacco B, Rubini E, Foddai S, Padovan M, Gallo Cassarino S, Franceschini F, Andrade D, Benedetto C, Govoni M, Bertero T, Marozio L, Roccatello D, Andreoli L, Sciascia S. A Multicentre Study of 244 Pregnancies in Women with Undifferentiated Connective Tissue Disease: Foetal/Perinatal and Maternal Outcomes and Disease Evolution Towards a Definite Connective Tissue Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-multicentre-study-of-244-pregnancies-in-women-with-undifferentiated-connective-tissue-disease-foetal-perinatal-and-maternal-outcomes-and-disease-evolution-towards-a-definite-connective-tissue-disea/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-multicentre-study-of-244-pregnancies-in-women-with-undifferentiated-connective-tissue-disease-foetal-perinatal-and-maternal-outcomes-and-disease-evolution-towards-a-definite-connective-tissue-disea/